uniQure N.V.
$18.04
▲
1.6%
2026-04-21 09:03:00
www.uniqure.com
NMS: QURE
Explore uniQure N.V. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.07 B
Current Price
$18.04
52W High / Low
$71.5 / $8.73
Stock P/E
—
Book Value
$3.19
Dividend Yield
—
ROCE
-24.65%
ROE
-2.07%
Face Value
—
EPS
$-3.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
221
Beta
0.75
Debt / Equity
269.78
Current Ratio
10.43
Quick Ratio
10.43
Forward P/E
-5.64
Price / Sales
59.74
Enterprise Value
$875.75 M
EV / EBITDA
-5.33
EV / Revenue
54.4
Rating
None
Target Price
$38.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Disc Medicine, Inc. | $71.41 | — | $2.74 B | — | -30.64% | -35.86% | $99.5 / $39.2 | $19.52 |
| 2. | Zentalis Pharmaceuticals, Inc. | $4.03 | — | $301.33 M | — | -57.45% | -49.54% | $6.95 / $1.13 | $3.13 |
| 3. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
| 4. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 5. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 6. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
| 7. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 5.57 M | 3.7 M | 5.26 M | 1.57 M | 5.22 M | — |
| Operating Profit | -51.49 M | -49.49 M | -42.88 M | -37.37 M | -46.1 M | — |
| Net Profit | -37.09 M | -80.53 M | -37.72 M | -43.64 M | -73.26 M | — |
| EPS in Rs | -0.59 | -1.29 | -0.6 | -0.7 | -1.17 | -0.91 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 16.1 M | 27.12 M | 15.84 M | 106.48 M |
| Operating Profit | -187.83 M | -182.18 M | -282.49 M | -144.25 M |
| Net Profit | -198.97 M | -239.56 M | -308.48 M | -126.79 M |
| EPS in Rs | -3.18 | -3.83 | -4.93 | -2.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 824.91 M | 556.54 M | 831.69 M | 704.96 M |
| Total Liabilities | 626.01 M | 563.29 M | 624.02 M | 228.96 M |
| Equity | 198.9 M | -6.75 M | 207.67 M | 476.01 M |
| Current Assets | 655.99 M | 390.29 M | 651.85 M | 476.77 M |
| Current Liabilities | 62.92 M | 40.05 M | 73.67 M | 75.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -177.96 M | -182.73 M | -145.93 M | -145.06 M |
| Investing CF | -321.62 M | 162.97 M | -205.69 M | -182.73 M |
| Financing CF | 415.4 M | -59.49 M | 362.72 M | 1.45 M |
| Free CF | -178.4 M | -194.42 M | -153.08 M | -162.75 M |
| Capex | -0.44 M | -11.69 M | -7.15 M | -17.69 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -40.64% | 71.17% | -85.12% | — |
| Earnings Growth % | 16.94% | 22.34% | -143.3% | — |
| Profit Margin % | -1236% | -883.35% | -1947.09% | -119.07% |
| Operating Margin % | -1166.77% | -671.78% | -1783.03% | -135.46% |
| Gross Margin % | 89.53% | 32.42% | 13.98% | 96.86% |
| EBITDA Margin % | -724.23% | -592.74% | -1597.55% | -101.44% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.